Reauthorizes the Accelerating Access to Critical Therapies for ALS Act through fiscal year 2031.
The Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 extends the provisions of the Accelerating Access to Critical Therapies for ALS Act through fiscal year 2031. It amends the Act to require the Food and Drug Administration to request interim clinical trial data from manufacturers of investigational drugs to assess the status of clinical trials.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
Analyze for Free
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.